Ocular Therapeutix Expects Key Wet AMD Phase 3 Data at Macula Society—Cash Runway and Multiple Trials Position Company for 2028

Cash Reserves Strengthen Ocular’s Position to Fuel Clinical Pipeline Through 2028

Ocular Therapeutix, Inc. enters 2026 with a robust cash position of $737.1 million, nearly doubling its reserves from $392.1 million at the prior year-end. The financial runway, further fortified by a $475 million equity raise last September, extends into 2028—enabling the company to advance multiple late-stage programs without requiring near-term fundraising.

Pivotal Phase 3 Data for AXPAXLI in Wet AMD Due by End of February

The most immediate catalyst for Ocular is the readout of key results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration (wet AMD). These masked 52-week results are expected to be presented at the 49th Macula Society Annual Meeting between February 25-28, 2026.

This trial could support the first U.S. product label for wet AMD with a superiority claim over a single dose of aflibercept (2 mg)—a potential step change in a market of 1.7 million U.S. wet AMD patients. Assuming positive data, Ocular aims to file a New Drug Application (NDA) leveraging the FDA’s 505(b)(2) pathway, potentially expediting review by up to two months.

Accelerated Timelines and Additional Programs Support Expansion

In December, the SOL-R Phase 3 non-inferiority trial for wet AMD completed randomization far ahead of schedule, enrolling 631 subjects versus the 555-target. Topline data are now anticipated in Q1 2027. Meanwhile, the HELIOS-3 Phase 3 trial in diabetic retinopathy (NPDR) is actively enrolling, and the SOL-X open-label trial—designed for longer-term follow-up—will start in Q2 2026.

This aggressive clinical strategy underscores Ocular’s intention to not only secure approval but also build a portfolio of data supporting broader and earlier use of AXPAXLI in retinal disease. The company is also considering a streamlined pathway for diabetic retinal diseases, potentially using only the ongoing HELIOS-3 study for approval in NPDR.

Revenue Pressured by Challenging Reimbursement, But DEXTENZA Maintains Strong Unit Volume

Despite record unit sales for its commercial product DEXTENZA in 2025, net revenue for the year dropped 18.5% to $52.0 million, reflecting a difficult reimbursement environment. This translated into a net loss of $265.9 million for the year, compared to a $193.5 million loss in 2024.

Near-Term Clinical Milestones Set the Tone for Commercial Future

The coming weeks will be pivotal, with the SOL-1 trial data expected to lay the groundwork for potential FDA submission and future commercialization efforts for AXPAXLI. Accelerated timelines for the SOL-R and HELIOS-3 trials add further near-term catalysts.

Ocular’s pipeline strategy—spanning wet AMD, NPDR, and future label expansions—reflects careful risk management and clinician engagement, including the incorporation of comprehensive screening and loading phases to de-risk pivotal studies.

Key Takeaway: Financial Flexibility Meets Clinical Momentum

While Ocular faces a challenging reimbursement environment and widening net losses, its robust cash reserves, expedited trial timelines, and data-driven execution place it in a strong position to influence the future of retinal disease treatment. Investors and clinicians alike should watch for the upcoming Phase 3 data at the Macula Society, which could set the stage for a new standard in wet AMD care and shape the company’s next chapter.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI